

blood[®]



ASH Abstracts
2020

Reprinted from:

2020 ASH Annual Meeting Abstracts *Blood 2020*

Selected abstract

Abstract 2116

**Matching-Adjusted Indirect Comparison (MAIC)
of Lisocabtagene Maraleucel (liso-cel)
Vs Axicabtagene Ciloleucel (axi-cel)
and Tisagenlecleucel in Relapsed/Refractory (R/R)
Large B-Cell Lymphoma (LBCL)**

David G. Maloney et al.

62nd ASH Annual Meeting and Exposition
December 5-8, 2020

© 2020

THE AMERICAN
SOCIETY OF
HEMATOLOGY

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD, PhD¹, John Kuruvilla, MD², Christopher P Fox, MD, PhD^{3*}, **Guillaume Cartron, MD, PhD^{4*}**, Daniel Li, PhD^{5*}, Jens Hasskarl, MD^{6*}, Ashley Bonner, PhD^{7*}, Yixie Zhang, PhD^{7*} and Fei Fei Liu, BSc, MBA^{8*}

¹Fred Hutchinson Cancer Research Center, Seattle, WA

²Princess Margaret Cancer Centre, Toronto, ON, Canada

³Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

⁴Centre Hospitalier Universitaire de Montpellier, Montpellier, France

⁵Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA

⁶Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland

⁷Eversana, Burlington, ON, Canada

⁸Bristol Myers Squibb, Princeton, NJ

*signifies non-member of ASH

Introduction: Chimeric antigen receptor T cell therapies have shown encouraging, durable responses in patients with R/R LBCL, yet no head-to-head clinical trials comparing options exist to date. We conducted 2 separate pair-wise MAICs to compare treatment effects of liso-cel vs both axi-cel and tisagenlecleucel.

Methods: MAICs were used to estimate population-adjusted relative treatment effects associated with liso-cel (TRANSCEND NHL 001 [TRANSCEND]; NCT02631044; N = 256) vs axi-cel (ZUMA-1; NCT02348216; N = 101) and vs tisagenlecleucel (JULIET; NCT02445248; N = 111). Outcomes of interest included efficacy (overall and complete response rates [ORR/CRR], overall survival [OS], and progression-free survival [PFS]) and safety (cytokine release syndrome [CRS] by Lee criteria, neurological events [NEs], aphasia, encephalopathy, infections, hypogammaglobulinemia, and prolonged cytopenia).

Individual patient data (IPD) from TRANSCEND were adjusted to match the marginal distribution (eg, mean, variance) of clinical factors among patients from ZUMA-1 and JULIET. Patients from TRANSCEND were removed from the IPD set if they did not satisfy eligibility criteria specified in the comparator trial for each MAIC. IPD for patients who remained in the TRANSCEND data set were weighted using a method-of-moments propensity score model. Baseline characteristic and outcome definitions were aligned with those in ZUMA-1 or JULIET. Clinically relevant prognostic factors (identified from literature, TRANSCEND data, and 5 independent clinical experts) were adjusted collectively in a stepwise fashion by ranked order. Key matched and adjusted variables in 1 or both comparisons included: disease histology, Eastern Cooperative Oncology Group performance status (ECOG PS), central nervous system (CNS) involvement, prior allogeneic/autologous hematopoietic stem cell transplant (HSCT), tumor burden, International Prognostic Index score, response to last therapy, bulky disease, and age. Efficacy outcomes in patients without bridging therapy were evaluated; however, ZUMA-1 and TRANSCEND treatment protocols differed in bridging therapy use (not allowed in ZUMA-1) and time to product availability (median, 17 vs 24 days, respectively).

Results: After aligning definitions of baseline characteristics among trials, substantial differences were noted for ECOG PS of 2, tumor burden, active CNS involvement, number of prior lines of therapy, prior allogeneic HSCT, and history of hematologic comorbidities between studies. Overall, TRANSCEND included a larger sample size and broader patient population vs comparator trials, allowing for successful MAIC adjustments.


When comparing TRANSCEND to ZUMA-1, MAIC-weighted efficacy outcomes were comparable between trials: odds ratios (ORs [95% CI]) for ORR and CRR with liso-cel vs axi-cel were 0.85 (0.48–1.52) and 0.78 (0.47–1.27), respectively; hazard ratios (HRs [95% CI]) for OS and PFS were 1.15 (0.80–1.65) and 1.30 (0.96–1.77), respectively (Figure). When limited to patients without bridging therapy, differences between trials remained statistically insignificant. MAIC-weighted safety outcomes showed a favorable safety profile for liso-cel, with a statistically significant lower odds of CRS, NEs (including aphasia and encephalopathy), and infections vs axi-cel. ORs (95% CI) for all-grade and grade ≥ 3 CRS with liso-cel vs axi-cel were 0.06 (0.03–0.13) and 0.16 (0.06–0.47), respectively; ORs for all-grade and grade ≥ 3 NEs were 0.21 (0.13–0.35) and 0.31 (0.18–0.54), respectively.

When comparing TRANSCEND to JULIET, liso-cel showed a statistically significant higher ORR/CRR and longer OS/PFS than tisagenlecleucel. ORs (95% CI) for ORR and CRR achieved with liso-cel vs tisagenlecleucel were 2.78 (1.63–4.74) and 2.01 (1.22–3.30), respectively; HRs (95% CI) for OS and PFS were 0.67 (0.47–0.95) and 0.65 (0.47–0.91), respectively. Adjusted safety

outcomes showed generally comparable profiles with lower ORs (95% CI) for all-grade and grade ≥ 3 CRS with liso-cel vs tisagenlecleucel: 0.53 (0.32–0.89) and 0.10 (0.03–0.31), respectively.

Conclusions: MAIC-weighted outcomes suggest that liso-cel may provide a more well-balanced overall efficacy and safety profile for the treatment of R/R LBCL, with better efficacy compared with tisagenlecleucel and better safety compared with axi-cel.

Figure. MAIC-Weighted Efficacy and Safety Outcomes



CRS, cytokine release syndrome; Est., estimate; HR, hazard ratio; MAIC, matching-adjusted indirect comparison; ND/PD SOC, nervous system disorders/psychiatric disorders by system organ class; NE, neurological event; OR, odds ratio.

Disclosures:

Maloney: *A2 Biotherapeutics*: Consultancy, Current equity holder in publicly-traded company, Honoraria; *Bioline Rx*: Consultancy, Honoraria; *Amgen*: Consultancy, Honoraria; *Genentech*: Consultancy, Honoraria; *MorphoSys*: Consultancy, Honoraria; *Pharmacyclics*: Consultancy, Honoraria; *Novartis*: Consultancy, Honoraria; *Gilead Sciences*: Consultancy, Honoraria; *Kite, a Gilead Company*: Consultancy, Honoraria, Research Funding; *Celgene*: Consultancy, Honoraria, Research Funding; *Juno Therapeutics*: Consultancy, Honoraria, Patents & Royalties: Patents are pending, but not issued, licensed, no royalties, no licensees., Research Funding. **Kuruvilla:** *Bristol-Myers Squibb Company*: Consultancy; *AbbVie*: Consultancy; *Antengene*: Honoraria; *TG Therapeutics*: Honoraria; *Novartis*: Honoraria; *Pfizer*: Honoraria; *Seattle Genetics*: Consultancy, Honoraria; *Gilead*: Consultancy, Honoraria; *Celgene Corporation*: Honoraria; *Amgen*: Honoraria; *Roche*: Consultancy, Honoraria, Research Funding; *Karyopharm*: Consultancy, Honoraria; *Merck*: Consultancy, Honoraria; *Janssen*: Honoraria, Research Funding; *AstraZeneca Pharmaceuticals LP*: Honoraria, Research Funding. Fox: *AstraZeneca*: Research Funding; *Celgene*: Research Funding; *Sunesis*: Research Funding; *AbbVie*: Honoraria, Research Funding; *Roche*: Honoraria, Research Funding; *Takeda*: Honoraria, Research Funding; *Gilead*: Honoraria, Research Funding; *Adienne*: Honoraria, Research Funding; *Atarbio*: Research Funding. **Cartron:** *F. Hoffmann-La Roche*: Consultancy, Honoraria; *Abbvie*: Honoraria; *Sanofi*: Honoraria; *Celgene*: Consultancy, Honoraria; *Gilead*: Honoraria; *Jansen*: Honoraria. **Li:** *Juno Therapeutics, a Bristol-Myers Squibb Company*: Current Employment; *Bristol-Myers Squibb*: Current equity holder in publicly-traded company. **Hasskarl:** *Bristol Myers Squibb*: Current Employment, Current equity holder in publicly-traded company. **Bonner:** *Eversana*: Current Employment. **Zhang:** *Eversana*: Current Employment. **Liu:** *Bristol-Myers Squibb*: Current Employment, Current equity holder in publicly-traded company.

All rights reserved. © 2020 by The American Society of Hematology
Cover image: © Sebastian Schreiter / Springer Medizin Verlag GmbH

Reprinted with permission from the American Society of Hematology, which does not endorse any particular uses of this document. The copyright in the contents and material in this publication is owned by American Society of Hematology as the Publisher. Although great care has been taken in compiling the content of this publication, neither Springer Healthcare, the Publisher or their agents are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies in the original or in translation, or for any consequences arising therefrom. Approved product information should be reviewed before use.



Springer Healthcare Ibérica S.L.

Rosario Pino, 14 - 4ª Planta. 28020 Madrid. Spain

Tel.: +34 91 555 40 62. Fax: +34 91 555 76 89

E-mail: Miguel.Quesada@springer.com

www.springerhealthcare.com

www.springernature.com

Part of the Springer Nature group